The UNC Breast Cancer SPORE's Developmental Research Program (DRP) promotes novel translational breast cancer research. The Program includes mechanisms for stimulating grant applications, evaluating and selecting projects, and monitoring progress. Drs. Lisa Carey, SPORE investigator and Medical Director of the UNC Breast Center, and Al Baldwin, SPORE investigator and UNC Lineberger Associate Director of Basic Science, oversee the DRP mechanisms for application, evaluation/selection, and monitoring. Application mechanisms include intra SPORE collaborations, Cancer Center-wide competitive-awards, and rapidly emerging opportunities. Evaluation and selection processes include independent peer review and consultation with SPORE senior leadership, external advisors, and advocates. The SPORE Director/Pi (Dr. Earp) and Co-Director/Co-Pi (Perou) make the final decisions regarding selection and budget. This DRP has been successful and effective. Since its inception in 1992, the UNC Breast Cancer SPORE has funded 42 projects. DRP projects have led to full-fledged SPORE projects and independently funded projects as well as publications. This report focuses primarily on outcomes from the most recent five years (Projects 30 - 42). During Years 15-19, UNC will commit $200,000 annually to developmental clinical, translational breast cancer research projects. We request $100,000 in SPORE funds to combine with $100,000 in institutional commitment to fund approximately three to five projects per year at $25,000 to $75,000/year. Funds for institutional commitment come primarily from the Cancer Center's Breast Cancer Research fundraising efforts. In Year 15 the program has identified two major projects for funding and will use established SPORE mechanisms, including the semi-annual competitive process, to make additional awards.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-17
Application #
7904777
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-08-01
Budget End
2010-07-31
Support Year
17
Fiscal Year
2009
Total Cost
$141,210
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, José Angel et al. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 24:5820-5829
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Kumar, Sunil; Lindsay, Daniel; Chen, Q Brent et al. (2018) Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ. NPJ Breast Cancer 4:39
Smith, Christof C; Beckermann, Kathryn E; Bortone, Dante S et al. (2018) Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J Clin Invest 128:4804-4820
Wheeler, Stephanie B; Spencer, Jennifer C; Pinheiro, Laura C et al. (2018) Financial Impact of Breast Cancer in Black Versus White Women. J Clin Oncol 36:1695-1701
Hong, Chi-Chen; Sucheston-Campbell, Lara E; Liu, Song et al. (2018) Genetic Variants in Immune-Related Pathways and Breast Cancer Risk in African American Women in the AMBER Consortium. Cancer Epidemiol Biomarkers Prev 27:321-330
Tanioka, Maki; Mott, Kevin R; Hollern, Daniel P et al. (2018) Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. Genome Med 10:86
Tanioka, Maki; Fan, Cheng; Parker, Joel S et al. (2018) Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res 24:5292-5304
Mundt, Filip; Rajput, Sandeep; Li, Shunqiang et al. (2018) Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. Cancer Res 78:2732-2746
Takaku, Motoki; Grimm, Sara A; Roberts, John D et al. (2018) GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. Nat Commun 9:1059

Showing the most recent 10 out of 598 publications